Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
Research output: Contribution to journal › Journal article › Research › peer-review
Background As studies on gastrointestinal neuroendocrine carcinoma (WHO G3) (GI-NEC) are limited, we reviewed clinical data to identify predictive and prognostic markers for advanced GI-NEC patients. Patients and methods Data from advanced GI-NEC patients diagnosed 2000-2009 were retrospectively registered at 12 Nordic hospitals. Results The median survival was 11 months in 252 patients given palliative chemotherapy and 1 month in 53 patients receiving best supportive care (BSC) only. The response rate to first-line chemotherapy was 31% and 33% had stable disease. Ki-67
| Original language | English |
|---|---|
| Journal | Annals of Oncology |
| Volume | 24 |
| Issue number | 1 |
| Pages (from-to) | 152-60 |
| Number of pages | 9 |
| ISSN | 0923-7534 |
| DOIs | |
| Publication status | Published - 2013 |
ID: 48501024